#457: Exploring the MedTech Commercial Valley of Death with Ryan O'Mahoney

Global Medical Device Podcast · 27 Apr 2026 · 35m · Episode 457

What this episode covers

Ryan O'Mahoney, founder of Catalyst Ventures and former VP at Precision X-Ray and Stryker, explains the 'commercial valley of death' in MedTech, where startups fail after FDA clearance due to underestimating institutional purchasing complexity. He argues that founders must integrate commercial strategy months before regulatory approval to align clinical data with operational ROI for hospital administrators and value analysis committees. O'Mahoney compares traditional full-time hiring, independent consulting, and distribution models, advocating for modern fractional commercial teams to preserve capital while building necessary momentum. He emphasizes that successful adoption requires navigating the gap between clinician enthusiasm and administrative budget constraints through early, structured engagement.

Other shows on the same ground, closest first.

  • Let's Combinate · 59m

    027 - "Become a Historian of the Problem" with Duane Mancini

    Duane Mancini, CEO and Managing Partner of Project Medtech, discusses his transition from medicinal chemistry to medical device regulatory strategy at NAMSA and LabCorp. He explains the critical importance of integrating reimbursement strategy early in the development of combination products to avoid commercialization failures, noting that regulatory choices like 510(k) can negatively impact reimbursement pathways. Mancini details how Project Medtech supports startups through its podcasts, Startup Symposiums, and consulting services, focusing on capital raising, milestone mapping, and navigating the complexities of drug-device combinations like insulin patches.

  • Being an Engineer · 46m

    S5E8 Aaron Call | How to Find Money for MedTech Startups

    Aaron Call, founding principal of Jaunt, explains how his company helps MedTech startups navigate market intelligence and fundraising by focusing on customer discovery rather than just technical feasibility. He distinguishes between sustaining and disruptive innovation, detailing how Jaunt uses qualitative and quantitative research to validate product-market fit for Class I and II devices. Call also outlines the current venture capital landscape, noting the shift toward funding only exceptional companies, and discusses the integration of AI in healthcare administration and device development.

  • Being an Engineer · 40m

    S2E40 Voice of the Customer, Using Questions, and the Technology Adoption Life Cycle Curve | Ted Newill

    Ted Newill, founder of Medical Device Success and SRD Vision, discusses the critical importance of 'Voice of the Customer' and the Technology Adoption Life Cycle Curve for medtech startups. He explains how engineers can bridge the gap between regulatory approval and commercialization by identifying early adopters and key opinion leaders before launch. Newill also shares advice on managing the pressure of venture-funded environments and the necessity of empathy and listening when collaborating with marketing and sales teams.

  • Being an Engineer · 39m

    S4E47 Mark Byrne | Startup Engineering, Funding, & Assumptions

    Mark Byrne, founder of PriMedicus Development, discusses his experience leading early-stage life sciences and medical device companies, covering strategies for market validation, securing funding, and managing engineering teams. He emphasizes the importance of direct customer interaction over third-party research, using development contracts with early adopters to de-risk technology before seeking venture capital. Byrne also shares lessons from a failed food safety sensor project and a successful genetic testing product licensed from Mayo Clinic, highlighting the critical role of technical expertise and customer relationships in startup success.

  • Let's Combinate · 22m

    133 - A Year of Saying No, Advice & Good MedTech Consulting, Humility in Leadership, andToxicity in Teams with Devon C. Campbell

    Devon Campbell, Founder of Prodct LLC and CPO of myBiometry, explains his transition from exiting MedTech ventures to founding a consulting firm focused on medical devices and diagnostics. He details his 'year of saying no' strategy, which allowed him to curate high-impact startup engagements while avoiding the toxic consultant culture he previously experienced. Campbell emphasizes humility in leadership, arguing that arrogance is a primary source of team dysfunction and that effective consulting requires authentic, humble facilitation rather than just technical oversight. He also discusses the specific operational challenges early-stage startups face, such as underestimating regulatory and quality system needs.

The summary, chapters and topics are generated from the episode’s audio by this directory, not written by Global Medical Device Podcast. The episode itself belongs to its publisher.